肌肉测量与PG-SGA评估在胃癌患者营养评估中的相关性研究

doi:10.16689/j.cnki.cn11-9349/r.2020.02.010

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (460 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨骨骼肌指数（SMI）及骨骼肌密度（SMD）与患者主观整体评估（PG-SGA）在胃癌患者营养评估中的相关性。方法在全国肿瘤患者营养调查平台纳入2017年1月至2019年11月武汉大学中南医院的118例胃癌患者作为主要研究对象，收集其基本信息和营养评分，通过我院影像科影像归档和通信系统（PACS）纳入符合要求的第三腰椎层面的影像学图像，计算SMI及SMD的数值；最后运用 Pearson相关分析法分析SMI、SMD与PG-SGA评分的相关性。结果 118例胃癌患者SMI均值为（34.34±8.01）cm2/m2，95%CI=32.78~35.84，SMD均值为（42.44±7.34）HU，95%CI=41. 06~43.97，男性均高于女性（P<0.05）；PG-SGA评分范围在1~20分之间，均值为（6.73±4.30）分，95%CI=5.91~7.56；SMI与PG-SGA评分具有显著负相关性（相关系数r=-0.608，P<0.001），但SMD与PG-SGA评分无明显相关性（r=-0.045，P=0.651）。结论在胃癌中， SMI与PG-SGA这两种评估方式对患者营养状况的评定具有一致性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	彭海艳
	戴静
	王文博
	彭晋
	夏泠
	李怡
	谢丛华
	许红霞
	石汉平
	周福祥

关键词 ：骨骼肌指数, 骨骼肌密度, 胃癌患者, 营养评估

Abstract：Objective To investigate the correlation between skeletal muscle index （SMI）， skeletal muscle density （SMD） and PG-SGA scores in nutrition assessment among gastric cancer patients. Methods A total of 118gastric cancer patients from Zhongnan Hospital of Wuhan University from January 2017 to November 2019 were screened and included from National Cancer Patient Nutrition Survey Platform. The nutrition scores and other basic information were collected， and then we passed through the PACS system in the imaging department of our hospital to find the images in the 3rd lumbar spine plane that we needed. After finished calculating the SMI and SMD， Pearson correlation analysis was used to analyze the correlation between the PG-SGA score and SMI， SMD. Results Among these 118 patients with gastric cancer， the mean level of SMI was about （34.34±8.01）cm2/m2， 95% confidence interval （95%CI ） was from 32.78 to 35.84， and the average of SMD was （42.44±7.34）HU， 95%CI was from 41. 06 to 43.97. Men were both higher than women in the two characteristics （P<0.05）. PG-SGA scores ranged from 1 to 20， with an average of （6.73±4.30），and 95%CI was from 5.91 to 7.56. There was a significant correlation between SMI and PG-SGA scores （r=-0.608，P<0.01）， but there was no significant correlation between SMD and PG-SGA scores （r=-0.045，P=0.651）. Conclusion In gastric cancer， the SMI and PG-SGA are consistent in assessing the nutritional status of patients.

Key words： Skeletal muscle index Skeletal muscle density Gastric cancer patients Nutritional assessment

基金资助:国家重点研发计划项目（2017YFC1309200）

通讯作者: 周福祥，电子邮箱: happyzhoufx@sina.com

引用本文:

彭海艳，戴静，王文博，彭晋，夏泠，李怡，谢丛华，许红霞，石汉平，周福祥 . 肌肉测量与PG-SGA评估在胃癌患者营养评估中的相关性研究[J]. 肿瘤代谢与营养电子杂志, 2020, 7(2): 188-192.
Peng Haiyan， Dai Jing， Wang Wenbo， Peng Jin， Xia Ling， Li Yi，Xie Conghua，Xu Hongxia，Shi Hanping，Zhou Fuxiang. Skeletal muscle measurement and PG-SGA in nutritional assessment of patients with gastric cancer. Electron J Metab Nutr Cancer, 2020, 7(2): 188-192.

1.LIM S L，ONG K C，CHAN Y H，et al. Malnutrition and its impact on cost of hospitalization，length of stay，readmission and 3-year mortality［J］. Clin Nutr， 2012， 31（3）: 345-350.
2.ZHUANG C L，HUANG D D，PANG W Y，et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort［J］. Medicine （Baltimore）， 2016， 95（13）: e3164.
3.ARENDS J，BACHMANN P，BARACOS V，et al. ESPEN guidelines on nutrition in cancer patients［J］. Clin Nutr， 2017， 36（1）: 11-48.
4.SANTARPIA L，CONTALDO F，PASANISI F. Nutritional screening and early treatment of malnutrition in cancer patients［J］. J Cachexia Sarcopenia Muscle， 2011， 2（1）: 27-35.
5.RODRIGUES C S，CHAVES G V. Patient-Generated Subjective Global Assessment in relation to site，stage of the illness，reason for hospital admission，and mortality in patients with gynecological tumors［J］. Support care cancer， 2015， 23（3）: 871-879.
6.石汉平. 恶性肿瘤病人营养诊断及实施流程［J］. 中国实用外科杂志， 2018， 38（3）: 257-261.
7.JAGER-WITTENAAR H，OTTERY F D. Assessing nutritional status in cancer: role of the Patient-Generated Subjective Global Assessment［J］. Curr Opin Clin Nutr Metab Care， 2017， 20（5）: 322-329.
8.GALLOIS C，ARTRU P，LIEVRE A，et al. Evaluation of two nutritional scores’ association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study［J］. Eur J Cancer， 2019， 119: 35-43.
9.VOLPI E，SHEFFIELD-MOORE M，RASMUSSEN B B，et al. Basal muscle amino acid kinetics and protein synthesis in healthy young and older men［J］. JAMA， 2001， 286（10）: 1206-1212.
10.POPURI K，COBZAS D，ESFANDIARI N，et al. Body composition assessment in axial CT images using fem-based automatic segmentation of skeletal muscle［J］. IEEE Trans Med Imaging， 2016， 35（2）: 512-520.
11.CRUZ-JENTOFT A J，BAHAT G，BAUER J，et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing， 2019， 48（4）: 601.
12.CAAN B J， CESPEDES FELICIANO E M， PRADO C M， et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer［J］. JAMA Oncol， 2018， 4（6）: 798-804.
13.DEL FABBRO E，PARSONS H，WARNEKE C L，et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer［J］. Oncologist， 2012， 17（10）: 1240-1245.
14.IWASE T，SANGAI T，NAGASHIMA T，et al. Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients［J］. Cancer Med， 2016， 5（1）: 41-48.
15.PRADO C M，BARACOS V E，MCCARGAR L J，et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment［J］. Clin Cancer Res， 2009， 15（8）: 2920-2926.
16.RIER H N，JAGER A，SLEIJFER S，et al. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy［J］. Breast， 2017， 31: 9-15.
17.SHACHAR S S，DEAL A M，WEINBERG M，et al. Skeletal muscle measures as predictors of toxicity， hospitalization， and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy［J］. Clin Cancer Res， 2017， 23（3）: 658-665.
18.BOSHIER P R， HENEGHAN R，MARKAR S R，et al. Assessment of body composition and sarcopenia in patients with esophageal cancer: a systematic review and meta-analysis［J］. Dis Esophagus， 2018， 31（8）: 10.1093/dote/doy047.
19.ZHANG Y，WANG J P，WANG X L，et al. Computed tomography-quantified body composition predicts short-term outcomes after gastrectomy in gastric cancer［J］. Curr Oncol， 2018， 25（5）: e411-e422.
20.GINGRICH A，VOLKERT D， KIESSWETTER E，et al. Prevalence and overlap of sarcopenia， frailty， cachexia and malnutrition in older medical inpatients［J］. BMC Geriatr， 2019， 27， 19（1）: 120.
21.PRADO C M， LIEFFERS J R， MCCARGAR L J， et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study［J］. Lancet Oncol， 2008， 9（7）: 629-635.
22.LI Y， WANG W B， JIANG H G， et al. Predictive value of pancreatic dose-volume metrics on sarcopenia rate in gastric cancer patients treated with adjuvant chemoradiotherapy［J］. Clin Nutr， 2019， 38（4）: 1713-1720.
23.World Health Organization. Cancer，Available: https://www.who.int/zh/news-room/fact-sheets/detail/cancer. Accessed in September 2018.
24.NOMURA S， SAKAMOTO H， GLENN S， et al. Population health and regional variations of disease burden in Japan， 1990-2015: a systematic subnational analysis for the Global Burden of Disease Study 2015［J］. Lancet， 2017， 390（10101）: 1521-1538.
25.ESFAHANI A， SOMI M H， ASGHARI JAFARABADI M， et al. A new score for screening of malnutrition in patients with inoperable gastric adenocarcinoma［J］. Jpn J Clin Oncol， 2017， 47（6）: 475-479.
26.SHAW C， FLEURET C， PICKARD J M， et al. Comparison of a novel， simple nutrition screening tool for adult oncology inpatients and the Malnutrition Screening Tool （MST） against the Patient-Generated Subjective Global Assessment （PG-SGA）［J］. Care Cancer， 2015， 23（1）: 47-54.
27.SCHIESSER M， KIRCHHOFF P， MULLER M K， et al. The correlation of nutrition risk index， nutrition risk score，and bioimpedance analysis with postoperative complications in patients undergoing gastrointestinal surgery［J］. Surgery， 2009， 145（5）: 519-526.
28.KALAFATELI M， KONSTANTAKIS C， THOMOPOULOS K， et al. Impact of muscle wasting on survival in patients with liver cirrhosis［J］. World J Gastroenterol， 2015， 21（24）: 7357-7361.
29.ATKINS J L， WHINCUP P H， MORRIS R W， et al. Sarcopenic obesity and risk of cardiovascular disease and mortality: a population-based cohort study of older men［J］. J Am Geriatr Soc， 2014， 62（2）: 253-260.
30.DE OLIVEIRA NUNES TEIXEIRA V， FILIPPIN L I， VIACAVA P R， et al. Muscle wasting in collagen-induced arthritis and disuse atrophy［J］. Exp Biol Med （Maywood）， 2013， 238（12）: 1421-1430.
31.DERSTINE B A， HOLCOMBE S A， GOULSON R L， et al. Quantifying sarcopenia reference values using lumbar and thoracic muscle areas in a healthy population［J］. J Nutr， 2017， 21（10）: 180-185.
32.PINTO NETO L F， SALES M C， SCARAMUSSA E S， et al. Human immunodeficiency virus infection and its association with sarcopenia［J］. Braz J Infect Dis， 2016， 20（1）: 99-102.
33.YIP C， DINKEL C， MAHAJAN A， et al. Imaging body composition in cancer patients: visceral obesity， sarcopenia and sarcopenic obesity may impact on clinical outcome［J］. Insights Imaging， 2015， 6（4）: 489-497.
34.STENE G B， HELBOSTAD J L， AMUNDSEN T， et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer［J］. Acta Oncol， 2015， 54（3）: 340-348.
35.ZAMBRANO D N， XIAO J， PRADO C M， GONZALEZ M C. Patient-Generated Subjective Global Assessment and Computed Tomography in the assessment of malnutrition and sarcopenia in patients with cirrhosis: is there any association？［J］. Clin Nutr， 2019，S0261-5614（19）30274-30282.